A Phase II, Randomised, Open Label Study of Neoadjuvant Dabrafenib, Trametinib and / or Pembrolizumab in BRAF V600 Mutant Resectable Stage IIIB/C Melanoma
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 12 Sep 2017
At a glance
- Drugs Dabrafenib (Primary) ; Pembrolizumab (Primary) ; Trametinib (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms NeoTrio
- 12 Sep 2017 Trial design of the study presented at the 42nd European Society for Medical Oncology Congress.
- 11 Sep 2017 Trial design presented at the 2017 European Society for Medical Oncology Congress (ESMO) in Madrid, Spain, according to a Novartis media release.
- 28 Aug 2017 Planned initiation date changed from 1 Feb 2017 to 1 Oct 2017.